Does insulin resistance drive the association between hyperglycemia and cardiovascular risk?

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Færch, Kristine ^a,b   Bergman, Bryan ^b   Perreault, Leigh ^b  

^a STENO DIABETES CENTER   (Denmark)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE;

ADULT; ARTICLE; BODY FAT DISTRIBUTION; CARDIOVASCULAR RISK; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FRAMINGHAM RISK SCORE; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; ORAL GLUCOSE TOLERANCE TEST;

ADULT; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; HYPERGLYCEMIA; INSULIN RESISTANCE; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84862497106     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039260     Document Type: Article

References (31)

1. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M, (1998) Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction. New Engl J Med 339: 229-234.
2. Zoungas S, de Galan BE, Ninomiya T, Grobbee D, Hamet P, et al. (2009) Combined Effects of Routine Blood Pressure Lowering and Intensive Glucose Control on Macrovascular and Microvascular Outcomes in Patients With Type 2 Diabetes. Diabetes Care 32: 2068-2074.
3. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, et al. (2009) Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. New Engl J Med 360: 129-139.
4. The Action to Control Cardiovascular Risk in Diabetes Study Group (2008) Effects of Intensive Glucose Lowering in Type 2 Diabetes. New Engl J Med 358: 2545-2559.
5. Kodama S, Saito K, Tanaka S, Horikawa C, Fujiwara K, et al. (2012) Fasting and Post-Challenge Glucose as Quantitative Cardiovascular Risk Factors: A Meta-Analysis. J Atheroscler Thromb (http://dx.doi.org/10.5551/jat.10975).
6. Ning F, Tuomilehto J, Pyörälä K, Onat A, Söderberg S, et al. (2010) Cardiovascular Disease Mortality in Europeans in Relation to Fasting and 2-h Plasma Glucose Levels Within a Normoglycemic Range. Diabetes Care 33: 2211-2216.
7. Færch K, Borch-Johnsen K, Holst JJ, Vaag A, (2009) Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes? Diabetologia 52: 1714-1723.
8. Hills SA, Balkau B, Coppack SW, Dekker JM, Mari A, et al. (2004) The EGIR-RISC STUDY (The European group for the study of insulin resistance: relationship between insulin sensitivity and cardiovascular disease risk): I. Methodology and objectives. Diabetologia 47: 566-570.
9. DeFronzo RA, Ferrannini E, (1991) Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14: 173-194.
10. American Diabetes Association, (2012) Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 35: S64-S71.
11. Perreault L, Lavely JM, Bergman BC, Horton TJ, (2004) Gender differences in insulin action after a single bout of exercise. J Appl Physiol 97: 1013-1021.
12. Perreault L, Bergman BC, Playdon MC, la-Man C, Cobelli C, et al. (2008) Impaired fasting glucose with or without impaired glucose tolerance: progressive or parallel states of prediabetes? Am J Physiol Endocrinol Metab 295: E428-E435.
13. D'Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, et al. (2008) General Cardiovascular Risk Profile for Use in Primary Care. Circulation 117: 743-753.
14. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, et al. (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321: 405-412.
15. DECODE Study Group (2001) Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161: 397-405.
16. De Vegt F, Dekker JM, Ruhe HG, Stehouwer CDA, Nijpels G, et al. (1999) Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: The Hoorn study. Diabetologia 42: 926-931.
17. Smith NL, Barzilay JI, Shaffer D, Savage PJ, Heckbert SR, et al. (2002) Fasting and 2-hour postchallenge serum glucose measures and risk of incident cardiovascular events in the elderly: the Cardiovascular Health Study. Arch Intern Med 162: 209-216.
18. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA, (2008) 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. New Engl J Med 359: 1577-1589.
19. DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, et al. (2011) Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance. New Engl J Med 364: 1104-1115.
20. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, et al. (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366: 1279-1289.
21. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, et al. (2008) Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes. JAMA 299: 1561-1573.
22. Neiberg RH, Wing R, Bray GA, Reboussin DM, Rickman AD, et al. (2012) Patterns of Weight Change Associated with Long-Term Weight Change and Cardiovascular Disease Risk Factors in the Look AHEAD Study. Obesity doi:10.1038/oby.2012.33.
23. Goldberg RB, Temprosa M, Haffner S, Orchard TJ, Ratner RE, et al. (2009) Effect of Progression From Impaired Glucose Tolerance to Diabetes on Cardiovascular Risk Factors and Its Amelioration by Lifestyle and Metformin Intervention. Diabetes Care 32: 726-732.
24. Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP, (2000) Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 101: 975-980.
25. Reddigan J, Riddell M, Kuk J, (2012) The joint association of physical activity and glycaemic control in predicting cardiovascular death and all-cause mortality in the US population. Diabetologia 55: 632-635.
26. Abdul-Ghani MA, Matsuda M, Balas B, DeFronzo RA, (2007) Muscle and Liver Insulin Resistance Indexes Derived From the Oral Glucose Tolerance Test. Diabetes Care 30: 89-94.
27. Linton MF, Fazio S, (2003) A practical approach to risk assessment to prevent coronary artery disease and its complications. Am J Cardiol 92: 19i-26i.
28. DeFronzo RA, Abdul-Ghani M, (2011) Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am J Cardiol 108: 3B-24B.
29. Ray KK, Sattar N, (2009) Diabetes: Which risk engines should be used to assess patients with diabetes? Nat Rev Endocrinol 5: 302-303.
30. Chamnan P, Simmons R, Sharp S, Griffin S, Wareham N, (2009) Cardiovascular risk assessment scores for people with diabetes: a systematic review. Diabetologia 52: 2001-2014.
31. Kengne A, Patel A, Colagiuri S, Heller S, Hamet P, et al. (2010) The Framingham and UK Prospective Diabetes Study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) Study. Diabetologia 53: 821-831.